Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis. 1994

J Beyer, and S Schwartz, and G Barzen, and G Risse, and K Dullenkopf, and C Weyer, and W Siegert
Abteilung für Hämatologie/Onkologie, Universitätsklinikum Rudolf Virchow, Freien Universität Berlin, Germany.

Invasive pulmonary Aspergillus infections are increasingly recognized among severely neutropenic and/or immunosuppressed individuals. As the infections are usually acquired through the inhalation of Aspergillus conidia, at present prevention of invasive pulmonary aspergillosis consists mainly of the reduction of environmental exposure to aspergillus conidia. More recently, prophylaxis with amphotericin B aerosols has been investigated. Inhalations with amphotericin B aerosols significantly delayed mortality in an animal model of invasive pulmonary aspergillosis and high pulmonary concentrations of amphotericin B could be achieved. In man, pulmonary deposition of amphotericin B could also be demonstrated using commercially available nebulizers. Inhalations were well tolerated with little systemic absorption of the drug. In order to evaluate the efficacy of aerosol amphotericin B administrations for the prevention of invasive pulmonary aspergillosis, a prospective randomized trial has been initiated.

UI MeSH Term Description Entries
D008172 Lung Diseases, Fungal Pulmonary diseases caused by fungal infections, usually through hematogenous spread. Fungal Lung Diseases,Pulmonary Fungal Infections,Pulmonary Fungal Diseases,Fungal Disease, Pulmonary,Fungal Diseases, Pulmonary,Fungal Infection, Pulmonary,Fungal Infections, Pulmonary,Fungal Lung Disease,Lung Disease, Fungal,Pulmonary Fungal Disease,Pulmonary Fungal Infection
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D010316 Particle Size Relating to the size of solids. Particle Sizes,Size, Particle,Sizes, Particle
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000336 Aerosols Colloids with a gaseous dispersing phase and either liquid (fog) or solid (smoke) dispersed phase; used in fumigation or in inhalation therapy; may contain propellant agents. Aerosol
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone

Related Publications

J Beyer, and S Schwartz, and G Barzen, and G Risse, and K Dullenkopf, and C Weyer, and W Siegert
January 1996, Infection,
J Beyer, and S Schwartz, and G Barzen, and G Risse, and K Dullenkopf, and C Weyer, and W Siegert
June 1993, Antimicrobial agents and chemotherapy,
J Beyer, and S Schwartz, and G Barzen, and G Risse, and K Dullenkopf, and C Weyer, and W Siegert
April 1983, Problemy tuberkuleza,
J Beyer, and S Schwartz, and G Barzen, and G Risse, and K Dullenkopf, and C Weyer, and W Siegert
December 1995, Annals of hematology,
J Beyer, and S Schwartz, and G Barzen, and G Risse, and K Dullenkopf, and C Weyer, and W Siegert
January 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,
J Beyer, and S Schwartz, and G Barzen, and G Risse, and K Dullenkopf, and C Weyer, and W Siegert
August 1995, The European respiratory journal,
J Beyer, and S Schwartz, and G Barzen, and G Risse, and K Dullenkopf, and C Weyer, and W Siegert
October 1996, The Annals of pharmacotherapy,
J Beyer, and S Schwartz, and G Barzen, and G Risse, and K Dullenkopf, and C Weyer, and W Siegert
May 1997, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
J Beyer, and S Schwartz, and G Barzen, and G Risse, and K Dullenkopf, and C Weyer, and W Siegert
July 1990, Southern medical journal,
J Beyer, and S Schwartz, and G Barzen, and G Risse, and K Dullenkopf, and C Weyer, and W Siegert
January 1974, The American review of respiratory disease,
Copied contents to your clipboard!